Evidence map›Paper›PMID 37863720›Full record

ReviewTrends in cancer2024

The tumor-draining lymph node as a reservoir for systemic immune surveillance.

Ines Delclaux, Katherine S Ventre, Dennis Jones, Amanda W Lund

Open access · hybridAbstract readReview
In one paragraph

Review in Trends in cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
17.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Melanoma evolution in the lymph node shapes systemic outcomes.bioRxiv : the preprint server for biology · 2026
    Article
  8. Article
  9. Article
  10. Tumor-Induced PDPNInternational journal of molecular sciences · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Ines DelclauxRonald O. Perelman Department of Dermatology, New York University (NYU) Grossman School of Medicine, New York, NY, USA.
Katherine S VentreRonald O. Perelman Department of Dermatology, New York University (NYU) Grossman School of Medicine, New York, NY, USA.
Dennis JonesDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA. Electronic address: djones1@bu.edu.
Amanda W LundRonald O. Perelman Department of Dermatology, New York University (NYU) Grossman School of Medicine, New York, NY, USA; Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. Electronic address: amanda.lund@nyulangone.org.
New York University · USBoston University · USNYU Langone Health · US

Funding

Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIRCHHOFF, TOMAS · 2019 to 2025
$12.5M
Project 3: The Evolving Role of Regional Lymph Nodes in Melanoma ProgressionU54CA263001 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Eva Hernando · 2022 to 2026
$11.6M
NRSA Training CoreTL1TR001447 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MICOLI, KEITH J. · 2015 to 2025
$5.9M
Investigating T Cell Egress via Lymphatic Vessels in MelanomaR01CA238163 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUND, AMANDA W. · 2019 to 2023
$1.9M
NCATS NIH HHS TL1 TR001447NCI NIH HHS P50 CA225450NCI NIH HHS R01 CA238163NCI NIH HHS U54 CA263001
6 · The paper itself

Abstract

Early in solid tumor development, antigens are presented in tumor-draining lymph nodes (tdLNs), a process that is necessary to set up immune surveillance. Recent evidence indicates that tdLNs fuel systemic tumor-specific T cell responses which may halt cancer progression and facilitate future responses to immunotherapy. These protective responses, however, are subject to progressive dysfunction exacerbated by lymph node (LN) metastasis. We discuss emerging preclinical and clinical literature indicating that the tdLN is a crucial reservoir for systemic immunity that can potentiate immune surveillance. We also discuss the impact of LN metastasis and argue that a better understanding of the relationship between LN metastasis and systemic immunity will be necessary to direct regional disease management in the era of immunotherapy.

Indexed as

Lymph NodesT-LymphocytesHumansImmunotherapyLymphatic Metastasisimmune surveillanceimmunotherapylymph nodemetastasis

Identifiers

PMID37863720
PMCPMC10843049
OpenAlexW4387746488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.